<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073147</url>
  </required_header>
  <id_info>
    <org_study_id>ML40029</org_study_id>
    <nct_id>NCT04073147</nct_id>
  </id_info>
  <brief_title>Venetoclax and Obinutuzumab for Relapsed Primary CNS Lymphoma</brief_title>
  <acronym>VENOBI-CNS</acronym>
  <official_title>Chemotherapy Free Treatment With Venetoclax and Obinutuzumab for Relapsed Primary CNS Lymphoma Patients (VENOBI-CNS Study) - A Phase IB Study to Assess the Pharmacokinetics in the Cerebrospinal Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Stuttgart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Stuttgart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and
      obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IB study investigating the pharmacokinetics of the combination venetoclax and
      obinutuzumab in the cerebrospinal fluid of patient with relapsed primary CNS lymphoma. Three
      dosing groups of venetoclax (600mg, 800mg, and 1000mg) are planned; dosing of obinutuzumab
      will be 1000mg for each dosing group. 15 patients are planned being included from two centers
      in Germany.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Three sequential dosing groups. Starting with dosing group 1 (5 patients), followed by dosing group 2 (5 patients) if no dose limiting toxicities occur during dosing group 1, and finally followed by dosing group 3 (5 patients) if no dose limiting toxicities occur in dosing group 2</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of venetoclax and obinutuzumab</measure>
    <time_frame>day 3, 15, and 28</time_frame>
    <description>Serum concentration and CSF concentration (μg/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose limiting toxicities</measure>
    <time_frame>Within the first 6 weeks</time_frame>
    <description>Defined by CTCAE (version 5.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best lymphoma response achieved during induction</measure>
    <time_frame>During induction (3 months)</time_frame>
    <description>According to IPCG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival 1 (PFS1)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Time from the date of first dose until date of progression, relapse or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Time from the date of first dose until date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival 2 (PFS2)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time from the start of maintenance venetoclax treatment at week 12 until date of progression, relapse or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutational landscape of lymphoma</measure>
    <time_frame>At baseline</time_frame>
    <description>NGS test based on FoundationOne Heme® platform</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Primary CNS Lymphoma</condition>
  <arm_group>
    <arm_group_label>Dosing group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 600mg + Obinutuzumab 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 800mg + Obinutuzumab 1000mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosing group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax 1000mg + Obinutuzumab 1000mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Venetoclax per os</description>
    <arm_group_label>Dosing group 1</arm_group_label>
    <arm_group_label>Dosing group 2</arm_group_label>
    <arm_group_label>Dosing group 3</arm_group_label>
    <other_name>Venclyxto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>ObintuzumabIV</description>
    <arm_group_label>Dosing group 1</arm_group_label>
    <arm_group_label>Dosing group 2</arm_group_label>
    <arm_group_label>Dosing group 3</arm_group_label>
    <other_name>Gazyvaro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age at inclusion ≥18 to 80 years, in case of ECOG 0 to 1 age up to 85years

          2. Eastern Cooperative Group performance status (ECOG) ≤ 3

          3. Evaluable lymphoma manifestation in the CNS, either contrast-enhanced lesion in the
             brain parenchyma or measurable meningeal lesions.

          4. Biopsy proven CD20 positive PCNSL at initial diagnosis or previous relapse (re-biopsy
             at study inclusion is not mandatory for inclusion, but strongly recommended if time in
             remission is longer than 24 months).

          5. At least one prior HD-MTX containing chemotherapy application (MTX dosed at ≥ 1 g/m2
             body surface area) before progression or relapse.

          6. Confirmed lymphoma relapse according to the IPCG response criteria.

          7. Absolute neutrophil count (ANC) of at least 1'500/μl

          8. Platelet count of at least 50'000/μl

          9. Adequate liver (alanine aminotransferase [ALAT] and AST ≤ 3.0 x upper limit of normal
             [ULN] and total bilirubin ≤ 1.5 x ULN) and kidney function (estimated

             ≥ 30ml/min creatinine clearance according to Cockgroft-Gault formula)

         10. Written informed consent

         11. Recovery from toxicity from previous anti-lymphoma treatment to ≤grade 2

        Exclusion Criteria:

          1. Known allergy to venetoclax or other components of the formulation

          2. Known allergy to obinutuzumab or other components of the formulation

          3. Primary ocular lymphomas without brain parenchymal involvement

          4. Lymphoma relapse outside the CNS; extra CNS relapse needs to be ruled out by body CT
             scans (neck till pelvis) or PET-CT scans.

          5. Contraindications for lumbar puncture at the discretion of the clinical investigator

          6. Prior exposure to obinutuzumab or venetoclax

          7. Other additional anti-lymphoma treatment, e.g. chemotherapy or radiotherapy

          8. Active hepatitis B or C

          9. HIV seropositivity

         10. Chronicuseofimmunosuppressivedrugs,e.g.steroidsforsystemic autoimmune disease

         11. Active infections requiring treatment

         12. Other active malignancies (except non-melanoma skin cancer). Prior malignancies
             without evidence of disease for at least 5 years are allowed

         13. Patient is pregnant or breastfeeding, or expecting to conceive or father children
             within one year of finishing venetoclax and 18 months for obinutuzumab.

         14. Prior allogeneic haematopoietic stem cell or solid organ transplantation

         15. Participation in any other interventional clinical trial within the last 30 days
             before the start of this trial; simultaneous participation in registry and diagnostic
             studies is allowed

         16. Patient without legal capacity who is unable to understand the nature, significance
             and consequences of the trial

         17. Known or persistent abuse of medication, drugs or alcohol

         18. Personwhoisinarelationshipofdependence/employmentwiththesponsor or the investigator

         19. Administration of moderate or strong CYP3A inhibitors or inducers within 1 week of
             initiation of venetoclax dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerald Illerhaus, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Klinikum der Landeshauptstadt Stuttgart gKAö</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerald Illerhaus, Prof</last_name>
    <phone>+4971127830400</phone>
    <email>g.illerhaus@klinikum-stuttgart.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisabeth Schorb, MD</last_name>
    <phone>+4976127035360</phone>
    <email>elisabeth.schorb@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>venetoclax</keyword>
  <keyword>obinutuzumab</keyword>
  <keyword>pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will by made available on a data depository (e.g. https://datadryad.org/) after study completion and publication of results.</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>after study completion and publication of results.</ipd_time_frame>
    <ipd_access_criteria>not decided yet</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

